<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008263</url>
  </required_header>
  <id_info>
    <org_study_id>158200-18/7-1053-552</org_study_id>
    <nct_id>NCT05008263</nct_id>
  </id_info>
  <brief_title>Competitive Accuracy of Radiological Imaging Compared to Liver Biopsy in Patients With Liver Fibrosis</brief_title>
  <official_title>Competitive Accuracy of Radiological Imaging Compared to Liver Biopsy in Patients With Liver Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vilnius University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vilnius University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study &quot;Competitive Accuracy of Radiological Imaging Compared to Liver Biopsy in Patients&#xD;
      With Liver Fibrosis&quot; is designed to test the accuracy of non-interventional radiological&#xD;
      imaging and compare its results with the &quot;gold standard&quot; liver biopsy. This is prospective&#xD;
      non-randomized single patient group study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Actual">January 31, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ultrasound elastography comparison to histological examination of liver biopsy specimen</measure>
    <time_frame>Baseline only</time_frame>
    <description>Liver stiffness measured by ultrasound elastography (2D-SWE) in kPa is compared to histological examination of liver biopsy specimen at a single time point before initiating antiviral treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dynamic liver scintigraphy with 99mTc-mebrofenin comparison to histological examination of liver biopsy specimen I</measure>
    <time_frame>Baseline only</time_frame>
    <description>Dynamic liver scintigraphy with 99mTc-mebrofenin parameter liver clearance (%/min/m2) is compared to histological examination of liver biopsy specimen at a single time point before initiating antiviral treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dynamic liver scintigraphy with 99mTc-mebrofenin comparison to histological examination of liver biopsy specimen II</measure>
    <time_frame>Baseline only</time_frame>
    <description>Dynamic liver scintigraphy with 99mTc-mebrofenin parameter uptake time (min.) is compared to histological examination of liver biopsy specimen at a single time point before initiating antiviral treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dynamic liver scintigraphy with 99mTc-mebrofenin comparison to histological examination of liver biopsy specimen III</measure>
    <time_frame>Baseline only</time_frame>
    <description>Dynamic liver scintigraphy with 99mTc-mebrofenin parameter liver excretion (30 min./peak ratio) is compared to histological examination of liver biopsy specimen at a single time point before initiating antiviral treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of radiological imaging tests between each other I</measure>
    <time_frame>Baseline only</time_frame>
    <description>Liver stiffness measured by ultrasound elastography (2D-SWE) in kPa is compared to liver clearance measured by dynamic liver scintigraphy with 99mTc-mebrofenin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of radiological imaging tests between each other II</measure>
    <time_frame>Baseline only</time_frame>
    <description>Liver stiffness measured by ultrasound elastography (2D-SWE) in kPa is compared to tracer excretion measured by dynamic liver scintigraphy with 99mTc-mebrofenin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of radiological imaging tests between each other III</measure>
    <time_frame>Baseline only</time_frame>
    <description>Liver stiffness measured by ultrasound elastography (2D-SWE) in kPa is compared to tracer uptake time measured by dynamic liver scintigraphy with 99mTc-mebrofenin.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">72</enrollment>
  <condition>Liver Fibroses</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Patients with viral chronic liver disease at primary diagnosis</arm_group_label>
    <description>Patients with primary diagnosis of viral hepatitis B and hepatitis C who was referred for liver biopsy. All patients underwent liver shear wave elastography and dynamic liver scintigraphy evaluating liver physical and functional changes shortly prior to liver biopsy procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Liver elastography (2D-SWE)</intervention_name>
    <description>All patients were referred for 2D-SWE liver elastography and liver liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy.</description>
    <arm_group_label>Patients with viral chronic liver disease at primary diagnosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Liver scintigraphy with 99mTc-mebrofenin</intervention_name>
    <description>All patients were referred for 2D-SWE liver elastography and liver liver scintigraphy with 99mTc-mebrofenin prior to liver biopsy.</description>
    <arm_group_label>Patients with viral chronic liver disease at primary diagnosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with primary diagnosis of chronic viral liver disease who are referred treating&#xD;
        gastroenterologist/infectologist for liver biopsy prior to treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  chronic liver disease&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
          -  liver biopsy indicated by treating gastroenterologist/infectologist&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  non-corrected blood coagulation tests&#xD;
&#xD;
          -  acute liver disease&#xD;
&#xD;
          -  age below 18 years or above 80 years&#xD;
&#xD;
          -  disagreement to participate in the study&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Algirdas E Tamosiunas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vilnius University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vilnius University</name>
      <address>
        <city>Vilnius</city>
        <zip>211950810</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver fibrosis</keyword>
  <keyword>Liver cirrhosis</keyword>
  <keyword>Liver biopsy</keyword>
  <keyword>Shear wave imaging</keyword>
  <keyword>Dynamic liver scintigraphy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
    <mesh_term>Technetium Tc 99m mebrofenin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

